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Abstract
Background: Parkinson disease (PD) is characterized by the degeneration of nigrostriatal dopaminergic neurons. However,
postmortem evidence indicates that the pathology of lower brainstem regions, such as the pons and medulla, precedes
nigral involvement. Consistently, pontomedullary damage was implicated by structural and PET imaging in early PD.
Neurochemical correlates of this early pathological involvement in PD are unknown.
Methodology/Principal Finding: To map biochemical alterations in the brains of individuals with mild-moderate PD we
quantified neurochemical profiles of the pons, putamen and substantia nigra by 7 tesla (T) proton magnetic resonance
spectroscopy. Thirteen individuals with idiopathic PD (Hoehn & Yahr stage 2) and 12 age- and gender-matched healthy
volunteers participated in the study. c-Aminobutyric acid (GABA) concentrations in the pons and putamen were
significantly higher in patients (N=11, off medications) than controls (N=11, p,0.001 for pons and p,0.05 for putamen).
The GABA elevation was more pronounced in the pons (64%) than in the putamen (32%). No other neurochemical
differences were observed between patients and controls.
Conclusion/Significance: The GABA elevation in the putamen is consistent with prior postmortem findings in patients with
PD, as well as with in vivo observations in a rodent model of PD, while the GABA finding in the pons is novel. The more
significant GABA elevation in the pons relative to the putamen is consistent with earlier pathological involvement of the
lower brainstem. This study provides in vivo evidence for an alteration in the GABAergic tone in the lower brainstem and
striatum in early-moderate PD, which may underlie disease pathogenesis and may provide a biomarker for disease staging.
Citation: Emir UE, Tuite PJ, O ¨z G (2012) Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS. PLoS
ONE 7(1): e30918. doi:10.1371/journal.pone.0030918
Editor: Pranela Rameshwar, University of Medicine and Dentistry of New Jersey, United States of America
Received September 2, 2011; Accepted December 24, 2011; Published January 25, 2012
Copyright:  2012 Emir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Dana Foundation and the Minnesota Medical Foundation Research Fund 3444. The Center for MR Research is
supported by the National Center for Research Resources (NCRR) grants P41RR008079 and S10 RR026783, the Neuroscience Center Core Blueprint Award P30
NS057091 and Keck Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: emirx001@umn.edu
Introduction
Parkinson disease (PD) is a progressive neurodegenerative
disorder characterized by varying combinations of rest tremor,
rigidity, bradykinesia, and postural changes. The major pathologic
marker of PD is the degeneration of nigrostriatal dopaminergic
neurons which leads to a reduction in dopamine (DA) content
within the striatum [1]. While loss of the nigrostriatal dopaminer-
gic neurons represents a hallmark of PD, the pathological
involvement in PD is not restricted to these neurons. Thus, recent
evidence indicates that caudal brainstem structures are involved in
PD pathology even before the nigrostriatal pathology [2]. Several
neuropathological studies have reported the degeneration in non-
dopaminergic pathways, including serotonin [3] and noradrena-
line neurons of the pons [4]. In line with these postmortem
findings, the locus coeruleus (LC) of the pons was reported as the
most affected extrastriatal area in PD with reduction of
18F-dopa
uptake, which is thought to reflect the degeneration of neurons in
this structure [5,6]. In addition, recent studies of patients with
early PD revealed pontomedullary atrophy by voxel based
morphometry [7] and decreased T1 in the pontomesencephalic
junction, indicating neuronal loss in this area [8].
Motivated by these histological, positron emission tomography
(PET) and MRI findings indicative of early functional and
structural changes in PD, we sought to gain further insights into
biochemical alterations in this disease that are thought to precede
structural changes. We utilized in vivo proton magnetic resonance
spectroscopy (
1H MRS) that can non-invasively monitor alter-
ations in neurochemical levels and has been used to study
neurochemical alterations in PD with some success [9,10,11].
Most prior MRS investigations in PD reported few neurochem-
icals or their ratios, such as the N-acetylaspartate-to-creatine
(NAA/Cr) ratio, measured at 1.5 tesla (T) or 3T. For example,
only one prior study investigated pontine neurochemistry in PD
during life and reported no difference in the NAA/Cr ratio at 3T
between subjects with PD and controls [12]. MRS findings in
nigrostriatal structures were variable, most of them reporting no
differences in PD vs. controls [9,10,13,14,15]. On the other hand,
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found alterations in several metabolites such as the neurotrans-
mitters glutamate (Glu) and c-aminobutyric acid (GABA) [16,17].
If similar alterations in neurotransmitter systems are detectable in
patients, they could lead to increased understanding of PD
pathogenesis and serve as markers of progressive neuronal
dysfunction.
Challenges associated with MRS in deep brain nuclei in
humans include their location, small size and high iron content
[10]. High- and ultra-high field MRS in humans presents
additional challenges including short T2 values and limitations
on the maximum achievable transmit power. Therefore, while the
feasibility of quantifying ‘‘neurochemical profiles’’ in the human
brain at the ultra-high field of 7T was demonstrated previously
[18,19], such studies have primarily been restricted to superficial
volumes-of-interest (VOIs) in the occipital lobe. A recent study
demonstrated the feasibility of quantifying six metabolites by 7T
MRS in deep brain regions from clinical populations [20].
Subsequently, we overcame challenges associated with quantifying
neurochemical profiles of up to 15 metabolites from deep brain
regions at 7T, including those that are of interest for PD
pathology, such as the pons, the substantia nigra (SN) and the
putamen [21]. Therefore, the goal of the current study was to
investigate neurochemical alterations in these regions that are
thought to be progressively involved in PD pathology with MRS at
7T and specifically to determine if alterations in neurotransmitter
levels similar to those observed in animal models of PD would be
detectable in patients with mild-moderate PD.
Methods
Subjects
Thirteen individuals with mild–moderate PD (6 women and 7
men, 56610 years old, mean6SD) and 12 age-matched healthy
volunteers (7 women and 5 men, 5468 years old) participated in
the study after giving written informed consent using procedures
approved by the Institutional Review Board: Human Subjects
Committee of the University of Minnesota. Participants were not
demented (as assessed by the Mini Mental State Exam and
Montreal Cognitive Assessment) and mild-moderate disease
severity of patients was established with the Unified Parkinson
Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging (H&Y)
(Table 1). Patients with PD were off their usual antiparkinsonian
medications for 12 hours prior to imaging.
MR Protocol
MR experiments were performed using a 7T, 90-cm horizontal
bore magnet (Magnex) equipped with a Siemens console. A 16-
channel transmit/receive transmission line array head coil was
used [22]. Images acquired with a 1-mm isotropic resolution
MPRAGE sequence (repetition time TR=3 s, inversion time
TI=1.5 s, echo time TE=3.67 ms, 192 partition-encode steps,
256 phase-encode steps, 256 data points in the read direction,
nominal flip angle=6u, total acquisition time=6 min 58 s) were
used for the selection of the pons and putamen VOIs. Images
acquired with a transverse multislice turbo spin echo sequence
(field of view, 1806180 mm
2; TR=3 s; TE=93 ms; flip
angle=150u; slice thickness=3 mm; 48 slices; one average) were
used to select the SN VOI. Destructive B1
+ interferences in the
VOI were reduced by localized B1
+ shimming as described before
[21]. Spectra were measured with a short-echo stimulated echo
acquisition mode (STEAM) sequence (TE=8 ms, TR=5 s,
mixing time TM=32 ms) with variable power RF pulses with
optimized relaxation delays (VAPOR) water suppression and outer
volume saturation [21,23]. Spectra were acquired from posterior
pons (30610615 mm
3, number of transients NT=128), posterior
putamen (1268618 mm
3, NT=128) and SN (6613613 mm
3,
NT=384) (Fig. 1). Pons and putamen data were acquired in all
subjects while SN spectra were acquired from a subset of the
volunteers because this acquisition necessitated a second scanning
session and only 5 patients and 5 controls were able to participate
in a second scan. Pons and putamen data from 11 subjects in each
group were included in the final analysis because spectra from two
patients and one control volunteer were excluded in each case due
to unwanted coherences noted in the spectra. The selection of the
pons and putamen VOIs was based on MPRAGE images
reconstructed in three orthogonal planes. The boundaries of the
VOIs were traced in all slices and their orientation adjusted to
ensure that only pontine or putamenal tissue was included in the
VOI with minimal partial volume effects. The same procedure was
followed with turbo spin echo sequence images to select the SN
VOI although partial volume effects could not be fully eliminated
Table 1. Demographic and clinical characteristics of patients with PD and control subjects and spectral quality measures.
Pons Putamen Substantia Nigra
Control PD Control PD Control PD
(n=11) (n=11) (n=11) (n=11) (n=5) (n=5)
Male/Female 5/6 5/6 5/6 6/5 1/4 2/3
Age 52.768.7 54.469.6 54.068.0 55.969.8 54.4611.4 63.065.8
Age at PD onset NA 48.569.8 NA 50.369.4 NA 58.466.2
UPDRS
a part III in ‘‘off’’ state 0.160.3 30.669.2
* 0.160.3 28.268.2
* 0.060.0 30.867.8
*
Hoehn & Yahr Stage in ‘‘off’’ state 0.060.0 2.060.0
* 0.060.0 2.060.0
* 0.060.0 2.060.0
*
L-Dopa equivalent dosage (mg/day) NA 380.46298.9 NA 342.66298.2 NA 350.06395.2
Linewidth (Hz) 12.963.0 13.262.3 20.567.1 19.765.9 20.864.9 24.663.9
SNR
b 16.261.7 15.161.9 10.562.5 11.062.8 7.561.2 5.861.6
Values given as counts or as mean6SD, as appropriate. NA, not applicable. Statistically significant differences between patient and control groups are marked with.
*p,0.05.
aUnified Parkinson Disease Rating Scale.
bSignal-to-noise ratio of non-weighted spectra calculated by LCModel based on the NAA peak.
doi:10.1371/journal.pone.0030918.t001
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selected contralaterally to the more severely affected side of
patients with PD. The location of the putamenal VOI was chosen
based on the known pattern of dopamine depletion in PD.
Namely, dopamine depletion starts from the posterior putamen
and proceeds gradually to other parts of the striatum based on
18F-
dopa PET [24]. In addition, postmortem evidence demonstrates
more severe dopamine depletion in the posterior than the anterior
putamen [25,26]. The location of the pontine VOI was chosen
based on a previous voxel based morphometry study that indicated
atrophy in this region [7]. Localizer images were repeated at the
end of the measurement from each VOI to confirm negligible
gross motion of the volunteer.
Unsuppressed water spectra acquired from the same VOI were
used to remove residual eddy current effects and to reconstruct the
phased array spectra [27]. Singleshotspectrawerefirstaveragedover
16 scans prior to frequency alignment to the NAA methyl signal.
Determination of anatomical structures encompassed by
the VOI
To delineate exactly which nuclei were included in our VOI,
the MPRAGE and turbo spin echo images were registered by full
affine transformations to the MNI152 space (average T1 weighted
brain image constructed from 152 normal subjects at the
Montreal Neurological Institute, Montreal, QC, Canada) using
FSL-FLIRT (Oxford Centre for Functional Magnetic Resonance
Imaging of the Brain Software (FSL, www.fmrib.ox.ac.uk/fsl)
Linear Image Registration Tool) [28]. The registration matrix
was then used to transform the VOI data onto the MNI152
space. Coordinates and brain regions encompassed by the VOIs
were identified by using Talairach Daemon Labels of FSL [29].
The identification of nuclei included in the posterior pons and SN
VOIs was based on visual comparison with schematic drawings of
gross anatomy obtained from human brainstem atlas [30,31] and
a template of LC [32].
Metabolite quantification
Metabolites were quantified using LCModel [33,34]. The
model spectra of alanine (Ala), aspartate (Asp), ascorbate/vitamin
C (Asc), glycerophosphocholine (GPC), phosphocholine (PC),
creatine (Cr), phosphocreatine (PCr), GABA, glucose (Glc),
glutamine (Gln), Glu, glutathione (GSH), myo-inositol (myo-Ins),
lactate (Lac), NAA, N-acetylaspartylglutamate (NAAG), phos-
phoethanolamine (PE), scyllo-inositol (scyllo-Ins) and taurine (Tau)
were generated based on previously reported chemical shifts and
coupling constants [35,36]. Macromolecule spectra were acquired
from the occipital cortex of 5 volunteers using an inversion
recovery sequence (TR=2 s, TI=0.680 s) [37]. Metabolite
concentrations were obtained relative to an unsuppressed water
spectrum acquired from the same VOI assuming a water content
of 72% for pons, 78% for putamen and 76% for substantia nigra
[38,39]. Concentrations were not corrected for T1 and T2 effects
because long TR and ultra-short TE values were used. Metabolites
quantified with Crame ´r-Rao lower bounds (CRLB, estimated
error of the metabolite quantification) .50% were classified as not
detected, as suggested by the LCModel manual [40]. As a
secondary filter to select reliable metabolite concentrations, only
metabolites quantified with CRLB #50% in at least half of the
spectra from a brain region were reported. This leads to a selection
of neurochemicals with average CRLB #,30% (Fig. S1). If the
correlation between two metabolites was consistently high
(correlation coefficient ,20.5) in a given region, their sum was
reported, such as Glc + Tau, NAA + NAAG (tNAA, total NAA),
Cr + PCr (tCr, total creatine), GPC + PC (tCho, total choline).
Statistical Analysis
Statistical analyses were conducted using SPSS (SPSS, Chicago,
IL). MRS data from the two groups were compared using a one-
way analysis of variance for each metabolite concentration and
CRLB in each brain region. Due to the pilot nature of the study p-
values shown have not been adjusted for multiple testing.
Relationships between clinical scores and metabolite concentra-
tions were evaluated using Pearson correlation coefficients.
Measures of spectral quality (signal-to-noise ratio, SNR, and
linewidth) and demographic and clinical characteristics (age,
UPDRS and H&Y) of the two groups were compared using the
two-tailed, unpaired student’s t-test.
Results
Patient and control groups were not different with regards to
age and gender (Table 1). All patients had late onset, idiopathic
PD and were at H&Y stage 2, considered to be mild-to-moderate
disease severity. All but one of the patients were taking L-Dopa or
other antiparkinsonian medications that were held for 12 hours
prior to the MR scan.
Figure 1.
1H MR spectra obtained in one patient with PD with
STEAM (TR=5 s, TE=8 ms) from three VOIs. Processing: Recon-
struction of single scan free induction decays (FIDs) from phased array
data, frequency and phase correction of FID arrays, FID summation,
correction for residual eddy current effects, Gaussian multiplication
(s=0.1 s), Fourier Transform (FT), zero-order phase correction. Positions
of the VOIs are shown on T1 – weighted images for pons and putamen
and on a T2– weighted image for substantia nigra (SN). tNAA, total N-
acetylaspartate; tCho, total choline; tCr, total creatine; myo-Ins, myo-
inositol.
doi:10.1371/journal.pone.0030918.g001
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regions from a patient with PD. A VOI analysis was performed by
transforming each subject’s anatomical images to MNI152 space.
This approach normalizes brain position and shape and limits
variability of regions due to head size and position. Then, the
boundaries of VOIs were traced in the MNI space and the brain
regions encompassed by the VOIs were identified (Table 2). This
analysis showed that multiple noradrenergic and serotonergic
nuclei were included in the pons VOI and both pars compacta and
pars reticulata were included in the SN VOI.
Artifact free spectra with good SNR and spectral resolution and
excellent water suppression were obtained in all brain regions for
both patients and controls. The full width at half maximum and
SNR values determined by LCModel were not different between
patients and controls for any VOI (p.0.05, Table 1), therefore
spectral quality in patients with PD and controls was similar.
Spectral linewidths were broader in the putamen and SN than
those in the pons, indicative of the iron content in these regions
(Table 1). The spectral patterns were characteristic of each of the
brain regions; note for example the ratio of the creatine and
choline peaks in the pons vs. the putamen and SN spectra (Fig. 1).
This spectral quality enabled the quantification of a neuro-
chemical profile consisting of 11 metabolites in the pons and
putamen and 7 metabolites in the SN (Fig. 2a). The neurochemical
profiles from the SN did not show significant differences between
patients and controls. On the other hand, higher GABA
concentrations were detected in the pons (p,0.001,
1.660.4 mmol/g vs. 1.060.2 mmol/g) and putamen (p,0.05,
2.160.4 mmol/g vs. 1.660.2 mmol/g) in patients with PD relative
to controls (Fig. 3). No group differences were observed for the
other metabolites (Fig. 2a). To ensure that the quality of individual
spectra was sufficient to accurately assess these trends, averaged
spectra from the patient and control groups were quantified
identically and showed the same trends (Fig. 2b). Consistent with
higher GABA concentration in patients, the CRLB of GABA were
lower both in the pons (p,0.001, 20.165.0 vs. 32.166.8%) and
putamen (p,0.07, 21.265.9 vs. 27.466.1%) in patients with PD
relative to controls (Fig. S1).
There were no significant relationships between the GABA
concentrations and either the UPDRS scores (total and part III) or
H&Y scores for any of the VOIs.
Discussion
Here using ultra-high field MRS we demonstrate elevated
GABA levels in the pons and putamen of patients with mild-
moderate PD as compared to age- and gender-matched healthy
controls. The striatal GABA elevation is consistent with postmor-
tem findings in patients with PD [25] and with in vivo observations
in an animal model of PD [16,17]. The pontine GABA finding is
novel. Furthermore, the GABA elevation was greater in the pons
(64%) than in the putamen (32%). Data obtained from the SN in a
subset of the volunteers revealed no group differences.
Since Braak suggested a caudorostral progression of a-synuclein
pathology in PD starting in the medulla oblongata [2,41], only one
study has investigated the neurochemistry of the pons in PD with
MRS [12]. Ratios of NAA, creatine and choline were investigated
in this study, and no differences were seen between patients and
controls. Nonetheless, neuronal loss in the pons including the
noradrenergic neurons of the LC [4] and the serotonergic neurons
of the raphe nucleus [3] is a well documented postmortem finding.
Additionally, neuronal loss in the pons has been indicated by
several in vivo MRI studies as a reduction in the neuromelanin-
related signal localized to the LC [42] and atrophy of the pons/
medulla detected by voxel based morphometry [7]. Another recent
MRI study reported decreased T1 in the pontomesencephalic
junction [8] and concluded that gray matter loss was likely the
major determinant of this T1 decrease. Thus, a neurochemical
abnormality was expected in the caudorostral extent of the pons.
The most likely neurochemical alteration to indicate neuronal loss
would be a lower NAA level [43], which we did not observe, likely
due to partial volume effects. On the other hand, we did observe a
robust GABA elevation, indicating that this neurochemical
difference was more widespread within the pontine VOI. The
pontine VOI in this study encompassed some non-dopaminergic
brainstem nuclei, such as the right and left LC, the reticular
formation and the raphe nuclei (Table 2). It remains to be
determined if the GABA abnormality relates to changes in these
nuclei. Most likely this change is a result of alterations in several
classes of neurons of the brainstem. For instance, others have
shown a reduction in
18F-dopa uptake in the LC region in patients
with more advanced PD (H&Y 2–3) indicating a progressive loss of
noradrenergic terminal function [5,6,44]. In addition, a reduction
in median raphe serotonin 5-hydroxytryptamine receptor 1A
binding in PD has been reported [45]. Thus an elevated GABA
tone can plausibly contribute to a functional deficit in the LC and
raphe nuclei, which are under GABAergic regulation. Therefore,
elevated GABA levels in GABAergic interneurons and terminals
present in these nuclei [46,47] may suppress the activity of the
noradrenergic and serotonergic neurons that project to the SN.
Consequently this would affect the activity of the nigral
dopaminergic neurons that project to the striatum (Fig. 4). Taken
together, these data suggest that altered GABAergic regulation of
non-dopaminergic neurons of the pons may be relevant to PD.
Regarding our putamenal findings, postmortem studies of
individuals with advanced disease demonstrated elevated striatal
GABA levels, particularly in the putamen [25]. A negative
correlation between GABA and DA was observed in the putamen
in this postmortem work; suggesting that the striatal GABA
elevation was associated with dopaminergic terminal loss [25,48].
In line with the postmortem findings in patients, a significant
increase in GABA concentration was shown in the striatum of the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse
model of PD [16,17]. The involvement of striatal GABAergic
neurotransmission in PD was further evaluated by quantification
of messenger RNA coding for the 67 kDa isoform of glutamic acid
Table 2. The anatomical structures and nuclei encompassed
by the three VOIs identified using Talairach Daemon Labels of
FSL.
VOI Brain Regions
Pons Locus Coeruleus (Noradrenergic center)
Raphe Nuclei (Serotonergic center)
Medial Parabrachial Nucleus (Noradrenergic center)
Pontine Reticular formation
Abducens Nucleus
Nucleus Reticularis Centralis
Facial Nucleus
Putamen Posterior Putamen
Substantia Nigra Pars Compacta
Pars Reticulata
Ventral Tegmental Area
doi:10.1371/journal.pone.0030918.t002
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enzymes. A significant increase in GAD67 mRNA levels was
measured in the putamen of MPTP-treated monkeys and rats
relative to controls [49,50], consistent with elevated GABA
concentrations in this region. Interestingly, manganese-exposed
workers who are at high risk for PD also show significantly higher
GABA levels than controls in a brain region containing the
thalamus, putamen and globus pallidus [51]. In the current study
we showed that elevated striatal GABA is present in vivo in patients
with mild-moderate PD. This GABA elevation in the putamen
likely stems from striatal GABAergic neurons, rather than
GABAergic afferents, because the primary afferents to the striatum
are glutamatergic and dopaminergic, while the predominant cell
type in the striatum is the medium sized GABAergic spiny
neurons. Animal models of PD have shown that experimental
lesions of the dopaminergic nigrostriatal pathway result in elevated
striatal GABA content [52], which may explain the GABA
elevation observed in the putamen in PD. We did not observe a
relationship between GABA levels and disease severity based on
clinical measures. The lack of a correlation between GABA levels
and clinical scores is likely due to the similarity of the clinical stage
of our patients, i.e. a small dynamic range (all were at H&Y stage
Figure 2. Neurochemical profiles determined by LCModel fitting of (a) individual and (b) averaged spectra from the 3 regions-of-
interest in patients with PD and healthy controls. Only metabolites quantified with Crame ´r-Rao lower bounds (CRLB) #50% in at least half of
the spectra from a brain region were included in the profiles. Metabolites that were significantly different between the two groups are marked with
*p,0.05, **p,0.001 in (a). Error-bars: inter-subject SD in (a) and CRLB expressed as mmol/g in (b). Asc, ascorbate; GABA, c-aminobutyric acid; Gln,
glutamine; Glu, glutamate; GSH, glutathione; myo-Ins, myo-inositol; scyllo-Ins, scyllo-inositol; tNAA, total N-acetylaspartate; tCho, total choline; tCr,
total creatine; Glc, glucose; Tau, taurine.
doi:10.1371/journal.pone.0030918.g002
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in a wider range of disease stages. It remains possible that the
elevated GABA concentration in the posterior putamen is
secondary to a loss of nigrostriatal DA terminals, and therefore
may provide complimentary information to the striatal DA
depletion detectable by PET scanning [53]. Future cross-sectional
and longitudinal investigations of DA by PET and GABA by MRS
in parallel could aid in monitoring disease progression. In
addition, evaluation of individuals scanned on and off medication
may help clarify if the GABA elevation is secondary to DA loss.
While we scanned subjects off medications for 12 hours,
intermediate- and long-lasting effects of antiparkinsonian medica-
tions on the current findings cannot be excluded. Thus medication
effects can be limited by studying drug-naı ¨ve patients. Prospective
1H MRS studies to investigate the consequences of striatal GABA
alterations in other regions could also provide further insight.
Specifically, investigations of GABA concentrations in the medial
pallidal segment and motor thalamic nuclei would be critical since
these regions play an important role regarding the outputs of the
basal ganglia to the cerebral cortex.
The main limitation of our study is the small sample size. This
may have prevented the detection of neurochemical alterations in
the SN. Alternatively, the very small size of the VOI (,1 mL)
necessitated by the anatomy of the SN (resulting in low SNR), and
high iron content (causing broader intrinsic linewidths, Fig. 1,
Table 1) may have obscured neurochemical differences (note the
higher standard deviations in SN vs. putamen and pons in Fig. 2a).
Similarly, in a prior study of the SN at 4T, we had detected trends,
but no statistically significant neurochemical differences, between
10 patients with mild-moderate PD vs. 11 age- and gender-
matched healthy controls [10]. The SN VOI utilized in the
current study was ,half of the size of the VOI used in our prior
study [10] and also obliqued to better conform with nigral
anatomy.
We reported raw p-values here due to the pilot nature of the
study, although note that the GABA difference in the pons remains
significant after a strict Bonferroni correction for the multiple
metabolites measured (significance at p,0.05/11=0.0045) and
therefore the finding is robust. The difference in the putamen was
less significant, which may reflect the earlier involvement of the
pons in PD pathogenesis. Alternatively, the CRLB cut-off (CRLB
#50%) we used to select reliable concentrations may have biased
the GABA concentration estimates of controls in the putamen. In
the putamen, seven of eleven control subjects’ GABA concentra-
tions met our reliable quantification criterion and four subjects’
GABA concentrations had CLRB in the range of 50–55% and
hence were excluded from the analyses. These excluded GABA
concentrations were around ,1 mmol/g and their inclusion would
lower the average GABA concentration in the control group and
increase the significance level of the GABA difference in putamen
(p,0.001). On the other hand, a larger GABA difference in the
pons (52%) vs. the putamen (20%) was supported by evaluation of
averaged spectra (Fig. 2b) that overcomes issues with insufficient
SNR in spectra from individuals.
Recent developments involving editing techniques have allowed
reliable in vivo measurements of GABA without other overlapping
resonances in the human brain [54,55,56]. In this study, we chose
to utilize unedited spectroscopy to quantify a neurochemical
Figure 3. GABA concentrations in pons and putamen by
subject groups, together with means (boxes) and standard
deviations (error bars).
doi:10.1371/journal.pone.0030918.g003
Figure 4. Proposed changes in pontine-nigral-striatal pathways
in PD. Enhanced pontine GABAergic activity (wider arrows) onto
serotonergic (5HT) locus ceruleus (LC) and/or noradrenergic (NE) raphe
neurons could result in a reduction in excitatory outflow (dashed
arrows) to substantia nigral neurons. As a result, this may decrease
nigral dopaminergic activity to the striatum (indicated by thin dashed
arrow).
doi:10.1371/journal.pone.0030918.g004
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neuronal and glial markers, such as NAA and myo-inositol,
respectively, and in neurotransmitter levels, such as glutamate
and GABA. Based on the findings of the current study, future
studies can utilize edited spectroscopy to focus on measurements of
GABA in PD. However, edited MRS measurements of GABA
require larger VOI than those utilized here because of longer echo
times and consequently lower SNR. Also, edited GABA
measurements need to take potential differences in T2 between
patients and controls into account when interpreting concentra-
tion differences. Such potential T2 differences are negligible at the
ultra-short echo times used in the current study. While T2
differences between patients with PD and controls are unlikely for
the pons and putamen based on similar linewidths we observed
(Table 1), they could potentially confound the quantification of
GABA concentration using edited spectroscopy in the SN based
on the linewidths we observed in this VOI. Consistently, PD-
dependent iron deposition in SN has shown a strong correlation
with T2 shortening in this region [57].
In conclusion, the present study demonstrated an elevation in
pontine and putamenal GABA levels in mild-moderate PD that
may underlie aspects of disease pathogenesis and pathophysiology.
Whether these are primary or secondary alterations and the
impact of treatment on them remain to be determined. These
novel findings suggest that further studies with
1H MRS may aid in
assessing pathogenetic theories of PD and in disease staging
together with other noninvasive neuroimaging modalities.
Supporting Information
Figure S1 Crame ´r-Rao lower bounds (CRLB) from the 3
regions-of-interest in patients with PD and healthy controls. Only
metabolites quantified with CRLB #50% in at least half of the
spectra from a brain region were included. CRLB of metabolites
that were significantly different or showed a trend between the two
groups are marked with *p,0.07, **p,0.001. Error-bars: inter-
subject SD. Asc, ascorbate; GABA, c-aminobutyric acid; Gln,
glutamine; Glu, glutamate; GSH, glutathione; myo-Ins, myo-
inositol; scyllo-Ins, scyllo-inositol; tNAA, total N-acetylaspartate;
tCho, total choline; tCr, total creatine; Glc, glucose; Tau, taurine.
(TIF)
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